Argo Biopharma Recognized Among World's Most Innovative Companies by Fast Company in 2026 Argo Biopharma has been named one of the World's Most Innovative Companies by Fast Company for 2026, showcasing its commitment to groundbreaking therapeutic advancements.

Argo Biopharma Recognized Among World's Most Innovative Companies by Fast Company in 2026 #China #Shanghai #Innovation #Argo_Biopharma #siRNA

Ribo Life Science Expands siRNA Delivery Beyond the Liver with RiboPepSTAR™ Suzhou Ribo Life Science introduces RiboPepSTAR™, a groundbreaking technology that targets the delivery of siRNA to various organs, enhancing therapeutic outcomes.

Ribo Life Science Expands siRNA Delivery Beyond the Liver with RiboPepSTAR™ #China #Suzhou #siRNA #RiboPepSTAR #RiboLife

Ribo Life Science Unveils RiboPepSTAR™ for Targeted siRNA Delivery Beyond the Liver Ribo Life Science introduces RiboPepSTAR™, a breakthrough technology for targeted siRNA delivery, expanding beyond the liver to treat multiple organ conditions.

Ribo Life Science Unveils RiboPepSTAR™ for Targeted siRNA Delivery Beyond the Liver #China #Suzhou #siRNA #Ribo #RiboPepSTAR

🧬 Can we switch off a gene to prevent heart attacks and strokes?

💊 In our video interview, #RNA interference pioneer Victor Kotelianski explains how #siRNA became a new class of medicines and led to a therapy now used worldwide to lower cholesterol.

youtu.be/5nGmE4R4HBM

Codexis and Pharmaceutical Partner Collaborate on siRNA Manufacturing Using Eco Synthesis Platform Codexis, Inc. enters a pivotal agreement to manufacture 50 grams of siRNA via its ECO Synthesis platform for a pharmaceutical partner targeting cardiovascular therapies.

Codexis and Pharmaceutical Partner Collaborate on siRNA Manufacturing Using Eco Synthesis Platform #United_States #Redwood_City #siRNA #Codexis #ECO_Synthesis

Frontier Biotech Enters Exclusive Licensing Deal with GSK for siRNA Therapeutics In a significant move, Frontier Biotech has partnered with GSK, securing exclusive global rights to develop two innovative siRNA therapeutics.

Frontier Biotech Enters Exclusive Licensing Deal with GSK for siRNA Therapeutics #USA #Nanjing #GSK #siRNA #Frontier_Biotech

Frontier Biotech and GSK Formulate Bold New Era in siRNA Therapeutics Frontier Biotechnologies has signed an exclusive licensing deal with GSK for siRNA therapeutics, enhancing their global development strategy and potential market impact.

Frontier Biotech and GSK Formulate Bold New Era in siRNA Therapeutics #USA #Nanjing #GSK #siRNA #Frontier_Biotech

Frontier Biotech Partners with GSK for Innovative Therapeutics Licensing Frontier Biotech and GSK have finalized an exclusive licensing deal for two small interfering RNA therapeutics, indicating a major step in biopharmaceuticals.

Frontier Biotech Partners with GSK for Innovative Therapeutics Licensing #China #Nanjing #GSK #siRNA #Frontier_Biotech

Exclusive: Feng Zhang’s epigenetic editing startup shifts focus to siRNA obesity therapies Moonwalk Biosciences, founded by Feng Zhang and Alex Aravanis, shifts from epigenetic editing to siRNA drugs, targeting obesity through adipose tissue manipulation.

Two years ago, #CRISPR pioneer Feng Zhang and former Illumina Alex Aravanis launched Moonwalk Biosciences to develop #epigenetic editing therapies. Now the company is shifting its focus to #siRNA therapies for #obesity. More details in my story for @endpts.com: endpoints.news/epigenetic-e...

New study suggests siRNA approach could reverse age-related cellular decline without triggering dedifferentiation or cancer-related pathways.

longevity.technology/news/study-s...

#longevity #biotech #siRNA #reprogramming #rejuvenation

🩸 China aprueba #FitusiránSódico (#Saifeiyin) para la profilaxis de hemofilia A y B graves, con o sin inhibidores.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#Hemofilia #DeficienciaDelFactorVIII #DeficienciaDelFactorIX #SangradoRecurrente #ARNi #siRNA #DengYueMedicinasEnHongKong

Ribo Life Science Marks Major Milestone with Hong Kong Stock Exchange Listing Ribo Life Science has successfully listed on the Hong Kong Stock Exchange, showcasing strong investor confidence in their RNA technology.

Ribo Life Science Marks Major Milestone with Hong Kong Stock Exchange Listing #Hong_Kong #siRNA #Ribo_Life_Science

Ribo Life Science Marks New Era by Listing on Hong Kong Stock Exchange Ribo Life Science has successfully listed on the Hong Kong Stock Exchange, marking a pivotal moment for the siRNA therapeutics industry and boosting investor confidence.

Ribo Life Science Marks New Era by Listing on Hong Kong Stock Exchange #Hong_Kong #siRNA #Ribo_Life_Science #Hong_Kong_Stock

Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAs Editor's choice: Comparison between five N-acetylgalactosamine-conjugated siRNAs in several mouse models of liver cancer found ANLN to be a promising target for hepatocellular carcinoma…

In August's #EditorsChoice, Gianna Maggiore, @haozhulab.bsky.social & co showed strong clinical potential in reducing #HepatocellularCarcinoma by targeting the actin-binding protein anillin via #siRNA knockdown in #MouseModel.

⚡ doi.org/10.1242/dmm....
📰 doi.org/10.1242/dmm....

Rona Therapeutics Launches First Bi-valent siRNA for Heart Disease Risk Reduction Rona Therapeutics has submitted RN5681 for clinical development, marking a revolutionary advancement in RNAi medicine aimed at reducing cardiovascular risk factors.

Rona Therapeutics Launches First Bi-valent siRNA for Heart Disease Risk Reduction #Australia #Santa_Barbara #Rona_Therapeutics #siRNA #RN5681

I just did a presentation on siRNA medicine, it uses short double stranded rna to bind to and trigger the degradation of mRNA transcript to silence genes and prevent certain proteins from being made. Research is ongoing for treatment of Alzheimer’s and ALS #sirna

🔬siRNA therapies are revolutionizing medicine!
Challenges: rapid degradation, poor biodistribution, cell barriers & off-target effects.Innovative delivery systems are the game-changer.
📍OTDC 2026|May25–26,Rome,Italy.
oligo-nucleotide.com
#siRNA #RNAresearch #Nanomedicine #Oligonucleotides #siRNA

🧬 Antiviral Oligonucleotides for Emerging Pathogens
🌍 Redefining the antiviral frontier!
Oligonucleotides bring speed, specificity, and innovation to fight emerging infectious threats.
📅 May 25–26, 2026 | 📍 Rome, Italy
🌐 oligo-nucleotide.com

#mRNAtherapeutics #OligoVaccine #siRNA #DNAbasedDrugs

Targeting clinical trials in metabolic dysfunction in 2026, gene-silencing approach seeks to reprogram diseased cells to a healthy state.

longevity.technology/news/junevit...

#longevity #investment #siRNA #biotech #reprogramming

Rona Therapeutics Unveils Promising Phase 1 Results for RN0361 at AHA 2025 Rona Therapeutics showcased Phase 1 findings for RN0361, a novel siRNA targeting ApoC3, at AHA 2025, showing excellent efficacy and safety.

Rona Therapeutics Unveils Promising Phase 1 Results for RN0361 at AHA 2025 #USA #New_Orleans #Rona_Therapeutics #RN0361 #siRNA

Remarkable, groundbreaking progress for cardiometabolic science and medicine!!! #FGF21R #GLP1 #APOC3 #ANGPTL3 #PCSK9 #mAb #siRNA #ASO #CRISPRCas9
Shoutout to ♥️ basic and clinical scientists moving this forward for our patients! @ahascience.bsky.social #AHA25 #PrevCards #Lipidology

First Patient Dosed in Phase 3 STOP-HAE Trial of ADX-324 ADX-324, a next-generation siRNA therapeutic for HAE, has entered phase 3 development with the first patient dosed in the STOP-HAE trial.

#ADX324, a next-generation small interference (#siRNA) therapeutic for hereditary angioedema (#HAE), has received #OrphanDrug Designation from the US FDA and entered phase 3 development, with the first patient dosed in the #STOPHAE trial.

Read more: https://bit.ly/43hyVPt

#RareDisease #MedSky

Joined University of Gothenburg as a Principal Investigator (PI). With that I begin an independent journey in #RNAthereapeutics and #extracellularvesicles

#Exosomes
#Lipidnanopartivles
#RNA
#mRNA
#RNAi
#siRNA

Vial Launches Phase 1 Trial for Novel INHBE siRNA to Combat Obesity Vial has initiated a Phase 1 trial for VIAL-INHBE, an innovative siRNA targeting obesity and metabolic diseases, aiming for safety and efficacy.

Vial Launches Phase 1 Trial for Novel INHBE siRNA to Combat Obesity #United_States #San_Francisco #obesity #siRNA #VIAL-INHBE

I’m attending #ASHG2025 in Boston this week! Excited to connect with researchers and innovators in genetics, drug target identification, and clinical development. I’ll be here until Saturday — let’s meet and explore collaboration opportunities!
#Genomics #DrugDiscovery #RNAi #siRNA

Uncertainty‑Guided Model Selection Improves Biomolecule Predictions

Using TabPFN's inter‑quantile range to pick low‑uncertainty models improves siRNA knockdown predictions, beating simple averaging. The pre‑print was posted on 2 Oct 2025. getnews.me/uncertainty-guided-model... #tabpfn #siRNA

The video 🎥 of the #BeilsteinTalk “Computational approaches in improving spermine-based RNA #nanocarriers" with Olivia Merkel, LMU München @lmumuenchen.bsky.social , is NOW available 🔓 in the video portal of the TIB Hannover:
🔗 https://av.tib.eu/media/71537
#DrugDelivery #siRNA #BeilsteinTalks

The video 🎥 of the #BeilsteinTalk “Computational approaches in improving spermine-based RNA #nanocarriers" with Olivia Merkel, Ludwig-Maximilians-Universität Munich, is NOW available 🔓 in the video portal @TIB_AVPortal of the @tibhannover.
🔗 […]

[Original post on hessen.social]

At Arnatar, we’re pioneering next-gen #RNAMedicines to treat severe & underserved diseases. Backed by our DARGER™ Platform, we advance antisense & #siRNA therapeutics that both up and down-regulate gene expression with precision.

Explore our pipeline: https://www.arnatar.com/pipeline

Rona Therapeutics Files IND for Innovative RN3161 siRNA Targeting Obesity Treatment Rona Therapeutics announces the IND filing for RN3161, an innovative siRNA for treating obesity while preserving muscle mass, marking a significant advancement in weight loss therapies.

Rona Therapeutics Files IND for Innovative RN3161 siRNA Targeting Obesity Treatment #USA #Santa_Barbara #Rona_Therapeutics #RN3161 #siRNA